Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis.

Chu R, Mills EJ, Beyene J, Pullenayegum E, Bakanda C, Nachega JB, Devereaux PJ, Thabane L.

AIDS Res Ther. 2013 Jul 13;10(1):19. doi: 10.1186/1742-6405-10-19.

2.

Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.

Hermans SM, van Leth F, Manabe YC, Hoepelman AI, Lange JM, Kambugu A.

HIV Med. 2012 Jul;13(6):337-44. doi: 10.1111/j.1468-1293.2011.00980.x.

3.

Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.

Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, Rutherford G, Mermin J.

AIDS. 2007 Mar 30;21(6):713-9.

PMID:
17413692
4.

Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.

Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, Santos J, Wells C, Paine P, Garrett D.

PLoS One. 2007 Sep 5;2(9):e826.

5.

Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.

Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J, Van Leth F, Mayanja-Kizza H, Kestens L, Mugerwa RD, Reiss P, Colebunders R; TB-IRIS Study Group..

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):32-7. doi: 10.1097/QAI.0b013e3182255dc2.

PMID:
21654499
6.

Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.

Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):42-6.

PMID:
16885778
7.

Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.

Schmaltz CA, Santoro-Lopes G, Lourenço MC, Morgado MG, Velasque Lde S, Rolla VC.

PLoS One. 2012;7(9):e45704. doi: 10.1371/journal.pone.0045704.

8.

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC.

AIDS. 2003 Dec 5;17(18):2615-22.

PMID:
14685055
9.

The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study.

Kerschberger B, Hilderbrand K, Boulle AM, Coetzee D, Goemaere E, De Azevedo V, Van Cutsem G.

PLoS One. 2012;7(10):e46988. doi: 10.1371/journal.pone.0046988.

10.

Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.

Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, Ntlamelle L, Seung KJ.

PLoS One. 2012;7(10):e46943. doi: 10.1371/journal.pone.0046943.

11.

Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC.

PLoS One. 2010 May 7;5(5):e10527. doi: 10.1371/journal.pone.0010527.

12.

HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study.

Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, Sattayawuthipong W, Burapat C, Kittikraisak W, Monkongdee P, Cain KP, Wells CD, Tappero JW.

BMC Infect Dis. 2009 Apr 13;9:42. doi: 10.1186/1471-2334-9-42.

13.

Operationalizing early antiretroviral therapy in HIV-infected in-patients with opportunistic infections including tuberculosis.

Sunpath H, Edwin C, Chelin N, Nadesan S, Maharaj R, Moosa Y, Smeaton L, Court R, Knight S, Gwyther E, Murphy RA.

Int J Tuberc Lung Dis. 2012 Jul;16(7):917-23. doi: 10.5588/ijtld.11.0651.

PMID:
22687498
14.

Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy.

Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo N, Gillini L, Zinzi D, De Luca A, Antinori A, Ippolito G.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):326-31.

PMID:
11317073
15.

Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.

Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F.

Int J Epidemiol. 2009 Dec;38(6):1612-21. doi: 10.1093/ije/dyp208.

16.

Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.

Franke MF, Robins JM, Mugabo J, Kaigamba F, Cain LE, Fleming JG, Murray MB.

PLoS Med. 2011 May;8(5):e1001029. doi: 10.1371/journal.pmed.1001029.

17.

Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome.

Conesa-Botella A, Loembé MM, Manabe YC, Worodria W, Mazakpwe D, Luzinda K, Mayanja-Kizza H, Miri M, Mbabazi O, Koole O, Kestens L, Colebunders R; TB IRIS Group..

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):463-8. doi: 10.1097/QAI.0b013e31823801de.

PMID:
21963941
18.

Predictors of antiretroviral treatment-associated tuberculosis in Ethiopia: a nested case-control study.

Mesfin N, Deribew A, Yami A, Solomon T, Van Geertruyden JP, Colebunders R.

Int J STD AIDS. 2012 Feb;23(2):94-8. doi: 10.1258/ijsa.2011.011051.

PMID:
22422682
19.

Impact of drug-resistant tuberculosis on the survival of HIV-infected patients.

Sungkanuparph S, Eampokalap B, Chottanapund S, Thongyen S, Manosuthi W.

Int J Tuberc Lung Dis. 2007 Mar;11(3):325-30.

PMID:
17352100
20.

Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.

Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, Karamagi CA.

BMC Health Serv Res. 2008 Nov 20;8:241. doi: 10.1186/1472-6963-8-241.

Items per page

Supplemental Content

Support Center